Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

[Rheumatology : what's new in 2022].

Iudici M., Lazarou I., Nissen MJ., Lauper K.

Randomized Controlled Trial on Autoimmune Research, published in Rev Med Suisse (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Rev Med Suisse (2023)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
36723656
DOI
10.53738/REVMED.2023.19.812.239

Abstract (original English)

In rheumatology, this year has seen an expansion of knowledge about the treatment of rheumatoid arthritis, with the availability of results from randomized trials evaluating a new molecule targeting IL-6, and regarding the safety profile of tofacitinib compared to TNF-alpha inhibitors. Interesting data on the outcome of pregnancy in patients with spondylarthritis have also been published. New molecules and different treatment strategies have shown promising results in psoriatic arthritis and systemic lupus erythematosus. The utility of botulinum toxin A injections for Raynaud's phenomenon and the efficacy of transplantation of autologous adipose-derived regenerative cells for the treatment of hand dysfunctions have been questioned by 2 randomized controlled trials of patients with systemic sclerosis. Cette année a vu un approfondissement des connaissances sur le traitement de la polyarthrite rhumatoïde, avec la publication de résultats d’essais randomisés évaluant une nouvelle molécule ciblant l’IL-6 et le profil de sécurité du tofacitinib par rapport aux inhibiteurs du TNF-alpha. Des données intéressantes sur l’issue de la grossesse chez les patientes atteintes de spondylarthrite ont également été publiées. De nouvelles stratégies de traitement ont donné des résultats prometteurs dans le rhumatisme psoriasique et le lupus érythémateux systémique. L’utilité des injections de to

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansRheumatologyBotulinum Toxins, Type AArthritis, RheumatoidLupus Erythematosus, SystemicScleroderma, Systemic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research